E-MTAB-2089 - Array CGH for treatment decision in metastatic breast cancer
Last updated on 20 November 2013, released on 4 April 2014
Breast cancer includes a large number of genomic segments defined by targetable genomic alterations. This multicentre molecular screening program aims to identify these abnormalities in individual patients in order to propose a targeted therapy matched to the genomic alteration.
genotyping by array, disease state design, ex vivo, genotype design
Array CGH and DNA sequencing for treatment decision in metastatic breast cancer: A multicentre, prospective trial (SAFIR01/UNICANCER).